Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multicenter Phase II Clinical Study to Evaluate the Safety and Efficacy of Almonertinib in Patients With Advanced NSCLC With Rare Mutations in EGFR

NCT04785742 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04785742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04785742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multicenter Phase II Clinical Study to Evaluate the Safety and Efficacy of Almonertinib in Patients With Advanced NSCLC With Rare Mutations in EGFR
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2020
Completion date
December 31, 2023
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety of almonertinib